Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)

LOS ANGELES, May 14 Vista Partners announced today that ithas initiated coverage on Synvista Therapeutics, Inc. (Amex: SYI). RossSilver, Director of Research of Vista Partners stated, "Synvista is one of thebest small cap investment opportunities investors will come across. Thecompany is conducting four Phase 2 trials in multi-billion dollar markets.Additionally their Hp test which will serve a ~$100M market, could begin toproduce revenues as early as next year. It is also important to note thatSynvista is led by a top tier management team who has taken compounds fromconcept to approval, a feat few management teams in small cap biotech haveachieved." To view the report on Synvista at no charge, please visit theVista Partners website at http://www.vistap.com and click on the downloadresearch icon located on top right hand corner of the home page.

About Vista Partners:

Vista Partners provides independent, equity research to institutional andindividual investors, with a focus on publicly traded small capitalizationcompanies. With offices in Los Angeles and San Francisco, Vista Partners isone of the fastest growing independently owned equity research firms. VistaPartners professional staff has backgrounds in finance, corporatecommunications and investment banking. More information is available athttp://www.vistap.com.

About Synvista Therapeutics, Inc.:

Synvista Therapeutics, Inc. is a product-based biotechnology companyengaged in the development of diagnostic tests and drugs to identify and treatdiabetic patients at high risk for the development of cardiovascular disease.The Company has identified several promising product candidates that itbelieves represent novel approaches for diagnosis and treatment in some of thelargest pharmaceutical markets. Currently, Synvista is advancing thedevelopment and commercialization of a diagnostic product and conducting Phase2 clinical trials for two of its other drug candidates. For more information,please visit the Company's website at http://www.synvista.com.Contact: Vista Partners LLC Ross Silver (310) 744-5268 [email protected] http://www.vistap.com

SOURCE Vista Partners

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...